NASDAQ:ARCT - Arcturus Therapeutics News Headlines Sign in or create an account to add this stock to your watchlist. Get Started $6.45 +0.22 (+3.53 %) (As of 05/27/2019 06:00 AM ET)Previous Close$6.45Today's Range$6.22 - $6.4552-Week Range$4.11 - $10.00Volume7,207 shsAverage Volume44,895 shsMarket Capitalization$69.41 millionP/E RatioN/ADividend YieldN/ABeta2.19 ProfileAnalyst RatingsChartDividendEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Headlines Arcturus Therapeutics (NASDAQ ARCT) News Headlines Source: All Sources Trusted Sources MarketBeat.com Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance DateHeadlineArcturus Therapeutics Presenting Data for ARCT-810 and the Arcturus mRNA + LUNAR® Technology Platform at the 2019 Annual Meeting of TIDES: Oligonucleotide and Peptide Therapeuticsfinance.yahoo.com - May 20 at 10:03 PMArcturus Therapeutics (ARCT) Posts Earnings Results, Misses Estimates By $0.15 EPSwww.americanbankingnews.com - May 14 at 10:21 AMArcturus Therapeutics (ARCT) Reports Q1 Loss, Tops Revenue Estimatesfinance.yahoo.com - May 13 at 7:31 PM$3.47 Million in Sales Expected for Arcturus Therapeutics Ltd (ARCT) This Quarterwww.americanbankingnews.com - May 5 at 8:30 PMArcturus Therapeutics Ltd (ARCT) Given Consensus Recommendation of "Buy" by Brokerageswww.americanbankingnews.com - May 5 at 3:39 PM-$0.44 Earnings Per Share Expected for Arcturus Therapeutics Ltd (ARCT) This Quarterwww.americanbankingnews.com - May 4 at 12:10 AMPhoenix Molecular Designs Appoints Magda Marquet, Ph.D. to its Board of Directorswww.prnewswire.com - March 21 at 10:52 AMArcturus Therapeutics Ltdwww.bloomberg.com - March 19 at 7:11 PMArcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Results - GlobeNewswireglobenewswire.com - March 19 at 9:11 AMArcturus Therapeutics Provides Corporate Update and Reports Fourth Quarter and Year End 2018 Financial Resultsfinance.yahoo.com - March 18 at 8:40 AMBRIEF-Arcturus Therapeutics Reassumes Full Worldwide Rights To Arct-810, A Clinical Development Candidate For Ornithine Transcarbamylase Deficiencywww.msn.com - March 2 at 8:34 AMArcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer - GlobeNewswireglobenewswire.com - January 4 at 10:49 AMArcturus Therapeutics (ARCT) to Develop ARCT-810 to Treat OTCD - StreetInsider.comwww.streetinsider.com - January 3 at 9:01 AMArcturus Therapeutics to develop ARCT-810 for treatment of OTCDseekingalpha.com - January 2 at 8:46 AMDo Insiders Own Lots Of Shares In Arcturus Therapeutics Ltd. (NASDAQ:ARCT)?finance.yahoo.com - December 21 at 5:09 PMActivists Having Busier-Than-Ever 2018 as Icahn Returns to Frayfinance.yahoo.com - December 18 at 8:50 AMMatriSys Bioscience appoints Magda Marquet, PhD to the Board of Directorsglobenewswire.com - November 12 at 8:39 AMArcturus Therapeutics Provides Corporate Update and Reports Third Quarter 2018 Financial Resultsfinance.yahoo.com - November 7 at 8:51 AMIs Arcturus Therapeutics Ltd (NASDAQ:ARCT) A Financially Sound Company?finance.yahoo.com - October 16 at 4:40 PMARCTURUS THERAPEUTICS LTD.www.streetinsider.com - October 2 at 4:38 PMArcturus Therapeutics (ARCT) Reports Q2 Loss, Lags Revenue Estimateswww.zacks.com - October 1 at 8:39 AMArcturus Therapeutics to Present at October Investor Conferencesfinance.yahoo.com - September 25 at 8:35 AMArcturus Therapeutics Expands Management Teamfinance.yahoo.com - September 21 at 8:47 AMArcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company's Independent Auditorwww.nasdaq.com - August 29 at 4:43 PMArcturus Therapeutics Announces Appointment of Ernst & Young LLP as the Company’s Independent Auditorfinance.yahoo.com - August 29 at 9:00 AMArcturus Therapeutics to Present at Three Investor Conferences in Septemberfinance.yahoo.com - August 27 at 9:03 AMAmerican Rct Reit (ARCT) Achieves Program Milestones, Refines Agreement with Cystic Fibrosis Foundation Therapeuticswww.streetinsider.com - July 24 at 9:16 AMArcturus Therapeutics Achieves Program Milestones and Refines Agreement with Cystic Fibrosis Foundation Therapeuticsfinance.yahoo.com - July 23 at 8:37 AMArcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Heldwww.nasdaq.com - July 21 at 8:28 AMArcturus Therapeutics Announces Annual and Extraordinary General Meeting of Shareholders to Be Held on August 24, 2018finance.yahoo.com - July 21 at 8:28 AMArcturus Therapeutics Announces Results of Extraordinary General Meeting of Shareholdersfinance.yahoo.com - July 9 at 8:34 AMArcturus Therapeutics to Present at the JMP Securities Life Sciences Conferencefinance.yahoo.com - June 18 at 9:59 AMWBB Securities Upgrades Arcturus Therapeutics (ARCT) to Buywww.streetinsider.com - June 11 at 4:56 PMUPDATE: Ladenburg Thalmann Upgrades Arcturus Therapeutics (ARCT) to Buy; Settlement Removes Overhangwww.streetinsider.com - May 31 at 5:08 PMAmerican Rct Reit (ARCT) Founder Joseph E. Payne Reinstated as President and CEO; Peter Farrell Named Chairmanwww.streetinsider.com - May 31 at 9:01 AMArcturus Announces Management Appointments; Company Founder Joseph E. Payne Reinstated as President and CEOfinance.yahoo.com - May 31 at 9:01 AMArcturus Appoints Four Directors And Reaches Settlement Deal With Founder Paynewww.nasdaq.com - May 29 at 5:01 PMArcturus Therapeutics Appoints Four New Directors and Reaches Settlement Agreement with Founder Joseph E. Paynefinance.yahoo.com - May 29 at 8:44 AMArcturus Therapeutics Founder Joseph Payne Calls for an End to Company’s Frivolous and Costly Lawsuits; Applauds Court Decision and Welcomes June 25, 2018 EGM Datefinance.yahoo.com - May 23 at 8:41 AMArcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary ...globenewswire.com - May 16 at 5:07 PMArcturus Therapeutics Files Form 20-Ffinance.yahoo.com - May 15 at 9:07 AMArcturus Therapeutics Founder Joseph Payne Welcomes Court Decision to Set Date and Agenda of Extraordinary General Meeting to Vote for New Board Membersfinance.yahoo.com - May 14 at 5:00 PMArcturus Therapeutics Founder Joseph Payne Successfully Prevents Board's Egregious Attempt to Dilute Shareholdersglobenewswire.com - May 3 at 4:58 PMBRIEF-Amir Efrati Reports 5.3 Percent Stake In Arcturus Therapeuticswww.reuters.com - May 1 at 8:53 AMBlog Exposure - Arcturus Initiates Lawsuit against Former CEO Joseph Payne for Misconduct and Violations of Federal Disclosurefinance.yahoo.com - April 24 at 5:13 PMBRIEF-Joseph Payne Says "Rejects" Arcturus Therapeutics' Board Of Directors' Latest Lawsuit Against Paynewww.reuters.com - April 23 at 4:54 PMArcturus Therapeutics Founder Joseph Payne Dismisses Board’s Baseless Lawsuit as Desperate Entrenchment Tacticfinance.yahoo.com - April 23 at 4:54 PMArcturus Therapeutics Files Lawsuit Against Joseph E. Payne and His Associates for Violations of Federal Securities ...globenewswire.com - April 20 at 5:00 PMBRIEF-Arcturus Therapeutics Files Lawsuit Against Former CEO Joseph Payne And His Associateswww.reuters.com - April 20 at 8:56 AMBRIEF-Joseph Payne Sent Letter To Arcturus Board To Restate Prior Demand To Convene EGMwww.reuters.com - April 19 at 8:46 AM This page was last updated on 5/27/2019 by MarketBeat.com StaffFeatured Article: Why is the ROA ratio important? Receive Analysts' Upgrades and Downgrades Daily Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.
